The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair deficiency setting, while safety and efficacy of combining dual-checkpoint inhibitor immunotherapy with chemotherapy remains uncertain. Here, we p...

Descripción completa

Detalles Bibliográficos
Autores principales: Renouf, Daniel J., Loree, Jonathan M., Knox, Jennifer J., Topham, James T., Kavan, Petr, Jonker, Derek, Welch, Stephen, Couture, Felix, Lemay, Frederic, Tehfe, Mustapha, Harb, Mohammed, Aucoin, Nathalie, Ko, Yoo-Joung, Tang, Patricia A., Ramjeesingh, Ravi, Meyers, Brandon M., Kim, Christina A., Du, Pan, Jia, Shidong, Schaeffer, David F., Gill, Sharlene, Tu, Dongsheng, O’Callaghan, Chris J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418247/
https://www.ncbi.nlm.nih.gov/pubmed/36028483
http://dx.doi.org/10.1038/s41467-022-32591-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418247/
https://www.ncbi.nlm.nih.gov/pubmed/36028483
http://dx.doi.org/10.1038/s41467-022-32591-8

Ejemplares similares